BrainsWay Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BWAY research report →
Range $19 – $20
Price Chart
About the company
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease.
- CEO
- Hadar Levy
- IPO
- 2019
- Employees
- 129
- HQ
- Jerusalem, JM, IL
Get TickerSpark's AI analysis on BWAY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $332.61M
- P/E
- 34.53
- Fwd P/E
- 28.91
- PEG
- 0.55
- P/S
- 5.17
- P/B
- 4.34
- EV/EBITDA
- 43.54
- Div Yield
- 0.00%
- Gross Margin
- 76.04%
- Op Margin
- 13.30%
- Net Margin
- 14.57%
- ROE
- 13.07%
- ROIC
- 9.29%
Latest fiscal year · YoY change
- Revenue
- $52.23M+27.3%
- Gross Profit
- $39.39M+28.8%
- Op Income
- $4.32M
- Net Income
- $7.63M+161.3%
- EPS
- $0.40+365.1%
- OCF Growth
- +76.4%
- FCF Growth
- +152.2%
- 52W High
- $17.40
- 52W Low
- $7.13
- 50D MA
- $11.85
- 200D MA
- $13.82
- Beta
- 0.15
- RSI (14)
- 28
- Avg Volume
- 109.38K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BrainsWay posted another strong quarter with 34% revenue growth, expanding margins, and management signaling continued momentum into 2027.· November 10, 2026
- Revenue rose 34% year over year to $18.1 million, with Q3 gross margin improving to 78% from 75%.
- Operating income increased 107% to about $2.6 million and adjusted EBITDA rose 92% to $3.9 million, showing stronger operating leverage.
- Installed base topped 2,000 systems, with 130 Deep TMS systems shipped in the quarter, up 44% year over year.
- RPO reached about $85 million, up 31% year over year, supporting visibility into future revenue.
- Management said full-year 2026 results are expected at the upper end of prior guidance, with a chance to modestly exceed it.
Third-quarter 2026 revenue was $18.1 million, up 34% from $13.5 million a year earlier; gross profit was $14.1 million versus $10.2 million, and gross margin expanded to 78% from 75%. Operating income increased 107% to about $2.6 million, operating margin rose to 14% from 9%, net income was $2.2 million versus $1.6 million, and adjusted EBITDA was $3.9 million versus $2.0 million, with adjusted EBITDA margin at 21% versus 15%. For the first nine months of 2026, revenue rose 35% to $50.8 million and operating income increased to about $7 million, with operating margin at 14% versus 6% last year. Management said full-year 2026 results should land at the upper end of the previously issued guidance range, with potential to modestly exceed those ranges; no specific next-quarter numerical guidance was provided.
Hadar Levy framed the quarter as evidence that BrainsWay is transitioning into a scalable, profitable neurostimulation platform rather than just a device seller. He emphasized expanding Deep TMS adoption, broader reimbursement, clinical evidence, and strategic partnerships as the key growth engines, and repeatedly pointed to stronger visibility from recurring revenue and enterprise relationships. His tone was upbeat and confident, especially around SWIFT, OCD, international expansion, and next-generation/home-use opportunities.
Ido Marom highlighted the hard numbers behind the quarter: revenue of $18.1 million, gross profit of $14.1 million, gross margin of 78%, operating income of about $2.6 million, and adjusted EBITDA of $3.9 million. He noted operating expenses rose to $11.5 million, including about $1 million of one-time share-based compensation and other nonrecurring payments, but said revenue growth outpaced expense growth. He also cited cash flow from operations of about $6.2 million, collections of $21.3 million, a cash balance of $63.4 million as of September 30, 2026, and said the company expects full-year results at the upper end of guidance, possibly modestly above it.
Analysts focused on ProlivRx/Neurolief commercialization, SWIFT adoption, 2027 margin durability, OCD demand, minority investments, and international growth. Management said Neurolief is progressing through distribution and commercial channels, with demand for a home-use complement to clinic-based treatment, while SWIFT demand is being driven by reimbursement coverage that now exceeds 70 million covered lives and close to 50% of new demand is already coming from SWIFT. On margins, management said gross margin should keep improving and op-ex should rise only 15% to 20% next year, while one analyst pressed for more detail on partnership economics; management said 2027 should bring more disclosure as partner locations mature and utilization gains have already been strong. For international and Alzheimer’s-related work, management pointed to growth in Latin America, Asia-Pacific, Europe, Japan, and said the Alzheimer’s feasibility work should run through end-2027, with any multicenter U.S. trial potentially costing $3 million to $4 million over 2.5 to 3 years.
The call showed broad-based momentum: higher revenue, better margins, stronger cash generation, and a larger installed base. Management also described expanding reimbursement for SWIFT and OCD, sustained enterprise and international opportunities, and multiple future growth drivers beyond the core business.
Management still has limited near-term disclosure on the revenue contribution from minority investments and partnerships, and much of that upside is expected to show more clearly in 2027. The Alzheimer’s program remains early and preliminary, Neurolief is still at an early commercialization stage, and some expansion opportunities depend on reimbursement, regulatory review, and partner execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.0%
- Shares Outstanding
- 39.22M
- Float Shares
- 29.42M
of shares held by institutions
58 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Valor Management LLC | 5.31M | 0 |
| Masters Capital Management LLC | 1.25M | ▼ 253.90K |
| Acadian Asset Management LLC | 769.37K | ▼ 38.56K |
| Renaissance Technologies LLC | 445.52K | ▼ 30.40K |
| Cresset Asset Management, LLC | 314.92K | 0 |
| Morgan Stanley | 250.71K | ▲ 61.74K |
| Y.D. More Investments Ltd | 224.38K | ▼ 13.05K |
| Eagle Global Advisors LLC | 182.61K | 0 |
| Legato Capital Management LLC | 176.57K | ▼ 21.07K |
| Ark Investment Management LLC | 146.85K | ▲ 4.35K |
| Jpmorgan Chase & Co | 127.02K | ▲ 30.21K |
| Sei Investments Co | 119.72K | 0 |
Held by 6 ETFs
Biggest fund positions in BWAY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 25, 26 | Moiseyev Gilad | other | 7,500 |
| May 25, 26 | Moiseyev Gilad | other | 1,902 |
| Jun 15, 26 | Moiseyev Gilad | sell | 5,000 |
| May 25, 26 | Moiseyev Gilad | other | 7,500 |
| May 25, 26 | Mitrany Rayten Michal Ety | sell | 10,000 |
| May 26, 26 | Mitrany Rayten Michal Ety | sell | 7,980 |
| May 20, 26 | Mitrany Rayten Michal Ety | other | 17,500 |
| May 20, 26 | Mitrany Rayten Michal Ety | other | 6,080 |
| May 19, 26 | Mitrany Rayten Michal Ety | other | 10,000 |
| May 19, 26 | Mitrany Rayten Michal Ety | other | 3,440 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BWAY coverage
Recent articles, reports, and earnings notes.
No research on BWAY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BWAY report →BrainsWay: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 11
What Brainsway (BWAY) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
BrainsWay Ltd. (BWAY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
globenewswire.com · Oct 28
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
globenewswire.com · Oct 26
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
globenewswire.com · Oct 19
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
globenewswire.com · Oct 13
HWG Holdings LP Buys New Stake in Brainsway Ltd. Sponsored ADR $BWAY
defenseworld.net · Oct 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.